This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Our Product Pipeline

Expanding Our Oncotype IQ Genomic Intelligence Platform to Transform Patient Management at Every Step of the Cancer Journey

Genetics and genomics are playing an increasingly critical role throughout all stages of cancer care, as evidenced by the impact of Oncotype DX, our industry-leading portfolio of expression tests. The most recently launched, Oncotype DX AR-V7 Nucleus Detect test, accurately detects AR-V7 proteins in the nucleus of the circulating tumor cells through a simple blood draw to help guide treatment decisions for men with metastatic castration-resistant prostate cancer (mCRPC).

Moving forward, Genomic Health will continue to transform cancer management through our own development and in partnership with others, expanding our Oncotype IQ Genomic Intelligence platform to include additional liquid and tissue-based tests. Through these pipeline efforts, we aim to answer a growing number of key patient questions at each of the many stages of cancer, including:

  • Do I have cancer cells in my body?
  • What is the precise classification of my cancer?
  • Is my disease responding to treatment? Is it still responding?
  • Has my cancer spread or metastasized or become resistant to my current treatment?
  • Is my disease still in remission?
  • Which therapy going forward may be the most effective for me?
  • Is my therapy having the desired effect?

Transforming cancer treatment across the patient journey with our robust product pipeline

Learn more about Genomic Health